Patents by Inventor Frank Emmrich
Frank Emmrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10577588Abstract: The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains.Type: GrantFiled: October 18, 2017Date of Patent: March 3, 2020Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Stephan Fricke, Frank Emmrich, Nadja Hilger
-
Publication number: 20190262396Abstract: The present invention relates to an unmodified graft, a modified graft and/or a CD4 antagonist (preferably a CD4 antibody) for use in a method of treating one or more disease(s) treatable by transplantation in a subject, wherein said method comprises a first step of introducing into said subject a modified graft, and a second step of introducing into said subject said unmodified graft, wherein said modified graft is a cell graft containing immune cells, wherein said modification impairs CD4. The present invention also relates to various further uses of an unmodified graft, a modified graft and/or a CD4 antagonist.Type: ApplicationFiled: February 15, 2017Publication date: August 29, 2019Inventors: Frank Emmrich, Stephan Fricke, Nadja Hilger
-
Patent number: 10227564Abstract: The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains.Type: GrantFiled: July 27, 2017Date of Patent: March 12, 2019Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Stephan Fricke, Frank Emmrich, Nadja Hilger
-
Publication number: 20180051254Abstract: The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains.Type: ApplicationFiled: October 18, 2017Publication date: February 22, 2018Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Stephan FRICKE, Frank EMMRICH, Nadja HILGER
-
Publication number: 20180030414Abstract: The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains.Type: ApplicationFiled: July 27, 2017Publication date: February 1, 2018Applicant: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.Inventors: Stephan FRICKE, Frank EMMRICH, Nadja HILGER
-
Patent number: 9745552Abstract: The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains.Type: GrantFiled: December 2, 2011Date of Patent: August 29, 2017Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Stephan Fricke, Frank Emmrich, Nadja Hilger
-
Patent number: 9585913Abstract: The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400° C. and 800° C., preferably between 500° C. and 700° C., in particular preferably at 550° C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min.Type: GrantFiled: May 31, 2013Date of Patent: March 7, 2017Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Furschung e.V.Inventors: Steffen Mitzner, Claus Kerkhoff, Frank Emmrich, Anne Breitruck, Peggy Bodammer, Gerd Kruger, Rainer Dallwig
-
Publication number: 20150258138Abstract: The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400° C. and 800° C., preferably between 500° C. and 700° C., in particular preferably at 550° C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min.Type: ApplicationFiled: May 31, 2013Publication date: September 17, 2015Applicant: FIM BIOTECH GmbHInventors: Steffen Mitzner, Claus Kerkhoff, Frank Emmrich, Anne Breitruck, Peggy Bodammer, Gerd Kruger, Rainer Dallwig
-
Patent number: 8986743Abstract: In a method for preparing an animal model for the human immune system in a non-human mammal, human stem cells with hematopoietic potential are transplanted into a non-human mammal. The non-human mammal is conditioned with cell culture supernatant of a culture of human cell lines, cells and/or tissue. The cell culture supernatant is derived from cell lines producing cytokines and other molecular mediators.Type: GrantFiled: May 17, 2006Date of Patent: March 24, 2015Assignee: Universität LeipzigInventors: Frank Emmrich, Manja Kamprad, Manuela Ackermann
-
Publication number: 20130330334Abstract: The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains.Type: ApplicationFiled: December 2, 2011Publication date: December 12, 2013Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Stephan Fricke, Frank Emmrich, Nadja Hilger
-
Publication number: 20110300069Abstract: The invention concerns the use of a labelled ligand having specificity for the human CD4 molecule to produce a diagnostic agent for analysing migration and/or distribution patterns of certain cell populations which comprise CD4-bearing cells in human individuals. In addition the invention concerns a composition which comprises a labelled ligand having specificity for the CD4 molecule and CD4-bearing cells or particles, and a method for determining the extent and progression of diseases in which human CD4-bearing cells are of clinical importance.Type: ApplicationFiled: August 17, 2011Publication date: December 8, 2011Applicant: BIOTECTID GMBHInventors: Frank Emmrich, Raimund W. Kinne, Rudiger Laub, Ullrich Pigla
-
Publication number: 20080216182Abstract: In a method for preparing an animal model for the human immune system in a non-human mammal, human stem cells with hematopoietic potential are transplanted into a non-human mammal. The non-human mammal is conditioned with cell culture supernatant of a culture of human cell lines, cells and/or tissue. The cell culture supernatant is derived from cell lines producing cytokines and other molecular mediators.Type: ApplicationFiled: May 17, 2006Publication date: September 4, 2008Applicant: UNIVERSITÄT LEIPZIGInventors: Frank Emmrich, Manja Kamprad, Manuela Ackermann
-
Publication number: 20050124005Abstract: The invention concerns the use of a labelled ligand having specificity for the human CD4 molecule to produce a diagnostic agent for analysing migration and/or distribution patterns of certain cell populations which comprise CD4-bearing cells in human individuals. In addition the invention concerns a composition which comprises a labelled ligand having specificity for the CD4 molecule and CD4-bearing cells or particles, and a method for determining the extent and progression of diseases in which human CD4-bearing cells are of clinical importance.Type: ApplicationFiled: December 9, 2002Publication date: June 9, 2005Applicant: BIOTECTID GMBHInventors: Frank Emmrich, Raimund Kinne, Rudiger Laub, Ullrich Pigla